Ishihara K
Institute for the Analyses of Prognostic Factors in Skin Cancer.
Gan To Kagaku Ryoho. 1999 Jun;26 Suppl 1:173-84.
The most common dermal malignancies are basal cell carcinoma, spinous cell carcinoma, and malignant melanoma, of which the latter two carry a poor prognosis. This communication deals with therapies for spinous cell carcinoma and malignant melanoma. Therapies for these malignancies have made huge strides, helping to formulate the policy and strategy for treatment and doing much to improve their prognoses. Chemotherapy, in particular, has become firmly established, contributing a great deal to the improvement of their prognoses. PEP, combination therapy with PEP plus MMC and CPT-11 are used for the treatment of spinous cell carcinoma, while CAV therapy is given to patients with advanced spinous cell carcinoma. In the treatment of malignant melanoma that is considered resistant to chemotherapy, DAV and PAV therapies have been attempted, and CDV and DACTam therapies have been tried on patients with advanced spinous cell carcinoma. Adoptive immunotherapy has also been used in the battle with this malignancy. Furthermore, excellent results have been observed with intratumor administration of IFN-beta. IFN-beta plus DAV has served well adjuvant therapy to improve the prognosis of Stage II or III malignant melanoma.
最常见的皮肤恶性肿瘤是基底细胞癌、棘状细胞癌和恶性黑色素瘤，其中后两者预后较差。本文论述棘状细胞癌和恶性黑色素瘤的治疗方法。这些恶性肿瘤的治疗取得了巨大进展，有助于制定治疗政策和策略，并在很大程度上改善了它们的预后。特别是化疗已牢固确立，对改善它们的预后贡献很大。PEP、PEP加MMC和CPT-11的联合疗法用于治疗棘状细胞癌，而CAV疗法用于晚期棘状细胞癌患者。在治疗被认为对化疗耐药的恶性黑色素瘤时，已尝试DAV和PAV疗法，并在晚期棘状细胞癌患者身上试用了CDV和DACTam疗法。过继性免疫疗法也已用于对抗这种恶性肿瘤。此外，瘤内注射IFN-β已观察到良好效果。IFN-β加DAV作为辅助疗法对改善II期或III期恶性黑色素瘤的预后效果良好。
